Pfizer’s Great Expectations: Sutent, Exubera Forecasts Exceed Those Of Investors
Firm projects 2010 annual sales of $2 bil. for the inhaled insulin and $1.5 bil. for the oncologic.
Firm projects 2010 annual sales of $2 bil. for the inhaled insulin and $1.5 bil. for the oncologic.